Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for Hard-to-Treat lymphomas

NCT ID NCT03598608

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in some participants. This is not a cure, but aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

137 people

The number who actually took part.

Started

Oct 2018

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has measurable disease, defined as ≥1 lesion that can be accurately measured in 2 dimensions with diagnostic quality cross sectional anatomic imaging (computed tomography or magnetic resonance imaging). Minimum measurement must be \>15 mm in the longest diameter or \>10 mm in the short axis * Is able to provide a core or excisional tumor biopsy for biomarker analysis from an archival (within 3 months) or newly obtained biopsy at screening * Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Exclusion Criteria: * Has known clinically active central nervous system (CNS) involvement * Has received prior therapy with an anti-lymphocyte activation gene-3 (LAG-3) antibody * Has received chimeric antigen receptors (CAR)-T-cell therapy for cHL and DLBCL Cohorts * Has received prior anticancer therapy or thoracic radiation therapy within 14 days before the first dose of study treatment * Has ≥Grade 2 non-hematological residual toxicities from prior therapy * Has had a prior anticancer monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to agents administered ≥4 weeks earlier * Has received a live vaccine within 30 days prior to first dose of study treatment. Administration of killed vaccines are allowed * Has received an investigational agent or used an investigational device within 4 weeks prior to intervention administration * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug * Has a known additional malignancy that is progressing or requires active treatment with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy * Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) * Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis * Has an active infection requiring intravenous systemic therapy * Has a known history of human immunodeficiency virus (HIV) infection * Has known, active hepatitis B or hepatitis C infection * Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment * Has had an allogeneic hematopoetic stem cell/solid organ transplantation within the last 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B-cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 B-cell neoplasm classic Hodgkin lymphoma diffuse large B-cell lymphoma Hodgkins lymphoma indolent B-cell non-Hodgkin lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hodgkin disease Lymphoma, B-cell Lymphoma, non-Hodgkin

Contacts and locations

Locations

  • A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 0351)

    Bologna, Emilia-Romagna, 40138, Italy

  • BC Cancer ( Site 0107)

    Vancouver, British Columbia, V5Z 1L3, Canada

  • Banner MD Anderson Cancer Center ( Site 0020)

    Gilbert, Arizona, 85234, United States

  • CancerCare Manitoba ( Site 0101)

    Winnipeg, Manitoba, R3E 0V9, Canada

  • Chaim Sheba Medical Center. ( Site 0380)

    Ramat Gan, 5262001, Israel

  • City of Hope ( Site 0001)

    Duarte, California, 91010, United States

  • Concord Repatriation & General Hospital ( Site 0203)

    Concord, New South Wales, 2139, Australia

  • Dana Farber Cancer Institute ( Site 0002)

    Boston, Massachusetts, 02215, United States

  • Fox Chase Cancer Center ( Site 0019)

    Philadelphia, Pennsylvania, 19111, United States

  • Hadassah Ein Karem Jerusalem ( Site 0383)

    Jerusalem, 9112001, Israel

  • Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0352)

    Rozzano, Milano, 20089, Italy

  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 0354)

    Meldola, Forli-Cesena, 47014, Italy

  • Jewish General Hospital ( Site 0105)

    Montreal, Quebec, H3T 1E2, Canada

  • Monash Health ( Site 0201)

    Clayton, Victoria, 3168, Australia

  • Pacific Cancer Care ( Site 0006)

    Monterey, California, 93940, United States

  • Princess Alexandra Hospital ( Site 0204)

    Woollongabba, Queensland, 4102, Australia

  • Princess Margaret Cancer Centre ( Site 0100)

    Toronto, Ontario, M5G 2M9, Canada

  • Rambam Medical Center ( Site 0382)

    Haifa, 3109601, Israel

  • Ronald Reagan UCLA Medical Center (Radiological Sciences) ( Site 0007)

    Los Angeles, California, 90095, United States

  • Sourasky Medical Center ( Site 0381)

    Tel Aviv, 6423906, Israel

  • St Vincent s Hospital (Melbourne) Limited ( Site 0202)

    Fitzroy, Victoria, 3065, Australia

  • Texas Oncology-Austin Midtown ( Site 8002)

    Austin, Texas, 78705, United States

  • U. klinikum Koeln AOER ( Site 0326)

    Cologne, North Rhine-Westphalia, 50937, Germany

  • Universitaetsklinikum Leipzig AOeR ( Site 0327)

    Leipzig, Saxony, 4103, Germany

  • University of California San Francisco ( Site 0023)

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.